Skip to content

Study · Animal study (in vivo) · dog · 2025

9 results

Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days.

Castro J, Shaikh I, Silo S, Hum C, Carrier M, DiFruscia R, Thouin F, Chan J, Aldana L, Garcia A, Berlanga J, Berryman L

Regulatory toxicology and pharmacology : RTP28 Feb 2025

PMID40024561 (opens in a new tab)DOI10.1016/j.yrtph.2025.105798 (opens in a new tab)PepBankPUB-40024561
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 caused transient, non-adverse hypersalivation in some animals at the higher doses.

    In plain wordsIn dogs, CIGB-500 produced temporary hypersalivation in some animals at the higher doses, considered non-adverse.

    Peptide
    GHRP-6
    Outcome
    Not applicableHypersalivation
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    1000 and 2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    2 context sentences
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 caused transient, non-adverse hypoactivity in some animals at the higher doses.

    In plain wordsIn dogs, CIGB-500 produced temporary reduced activity in some animals at the higher doses, considered non-adverse.

    Peptide
    GHRP-6
    Outcome
    Not applicableHypoactivity
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    1000 and 2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    2 context sentences
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 caused transient, non-adverse respiration changes in some animals at the higher doses.

    In plain wordsIn dogs, CIGB-500 temporarily changed breathing in some animals at the higher doses, considered non-adverse.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedRespiration changes
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    1000 and 2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    2 context sentences
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 caused transient, non-adverse pale gums in some animals at the higher doses.

    In plain wordsIn dogs, CIGB-500 produced temporary pale gums in some animals at the higher doses, considered non-adverse.

    Peptide
    GHRP-6
    Outcome
    Not applicablePale gums
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    1000 and 2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    2 context sentences
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 caused transient, non-adverse head region erythema in some animals at the higher doses.

    In plain wordsIn dogs, CIGB-500 produced temporary head redness in some animals at the higher doses, considered non-adverse.

    Peptide
    GHRP-6
    Outcome
    Not applicableHead region erythema
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    1000 and 2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    2 context sentences
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 did not produce adverse macroscopic changes.

    In plain wordsIn dogs, CIGB-500 did not produce adverse macroscopic changes.

    Peptide
    GHRP-6
    Outcome
    No significant changeAdverse macroscopic changes
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Treatment with CIGB-500 did not result in any adverse macroscopic or microscopic changes.
    1 context sentence
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 did not produce adverse microscopic changes.

    In plain wordsIn dogs, CIGB-500 did not produce adverse microscopic changes.

    Peptide
    GHRP-6
    Outcome
    No significant changeAdverse microscopic changes
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    Treatment with CIGB-500 did not result in any adverse macroscopic or microscopic changes.
    1 context sentence
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In dogs, CIGB-500 decreased heart rate at all dose levels.

    In plain wordsIn dogs, CIGB-500 reduced heart rate at all tested doses.

    Peptide
    GHRP-6
    Outcome
    DecreaseHeart rate during treatment
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    All dose levels · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    A decrease in heart rate value was noted following CIGB-500 treatment at all dose levels an at the end of recovery period, the heart rate effects at 2000 μg/kg/day were comparable to controls.
    3 context sentences
    Summary · context
    Hypersalivation, hypoactivity, reduced heart rate, changes in respiration, pale gums and erythema of the head region were observed in some animals administered at 1000 and 2000 μg/kg/day.
    Summary · context
    These clinical signs were transient, and were therefore considered non-adverse.
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In dogs, heart rate after recovery from CIGB-500 at 2000 μg/kg/day was comparable to controls.

    In plain wordsIn dogs, heart rate after recovery from CIGB-500 at 2000 μg/kg/day was similar to controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeHeart rate after recovery
    Study

    dogn: not reported in source

    Beagle dogs
    Comparator
    Controls
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2000 μg/kg/day · intravenous · 28 daysAs given in this study (dog).

    Source sentences

    Summary
    A decrease in heart rate value was noted following CIGB-500 treatment at all dose levels an at the end of recovery period, the heart rate effects at 2000 μg/kg/day were comparable to controls.
    1 context sentence
    Summary · context
    As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.